DNA錯配修復缺陷Mismatch Repair Deficiency（MMR-d）/高度微衛星不穩定性（MSI-H）可用來預測免疫治療的效率

 Dear family; ( sent out this email on Aug 2, 2020 )

Here is  a table of prevalence of MSI-H to see how rare (under 1%) is this for Non Small Cell Lung Cancer (Lung Adenocarcinoma) 肺腺癌 patients. 

God is very merciful, Praise the Lord!

 

We surely have a big reason to be thankful for. 

I believe God has started the healing in my brother Mark and He will do more amazing works. 

Let's pray for His fresh wonder daily! Let's keep praying earnestly!              Love, Biho

See more details about my brother Mark's miraculous story in the following link

哥哥零點五趴奇蹟的免疫治療 

LUSC (0.60%) lung squamous cell carcinoma,

   LUAD (0.53-1%) lung adenocarcinoma 肺腺癌

    I never realize that there are so many adenocarcinoma cancers. 

These following 3 cancers have the highest rate to respond to immunotherapy..

UCEC (17-31.37%) uterine corpus endometrial carcinoma, COAD(  6-19.72%) colon adenocarcinoma, 

STAD(9-19.09%) stomach adenocarcinoma, READ rectal adenocarcinoma,  

Table 1 Prevalence of MSI-H in 39 cancer types

https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0738-1/tables/1  

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

(The relationship between MMR and multiple tumors)

Immunotherapies have led to substantial changes in cancer treatment and have been a persistently popular topic in cancer research because they tremendously improve the efficacy of treatment and survival of individuals with various cancer types. However, only a small proportion of patients are sensitive to immunotherapy, and specific biomarkers are urgently needed to separate responders from nonresponders. Mismatch repair pathways play a vital role in identifying and repairing mismatched bases during DNA replication and genetic recombination in normal and cancer cells. Defects in DNA mismatch repair proteins and subsequent microsatellite instability-high lead to the accumulation of mutation loads in cancer-related genes and the generation of neoantigens, which stimulate the anti-tumor immune response of the host...

Table 1 Prevalence of MSI-H in 39 cancer types

From: Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

Cancer type	MSI-H (%)	Cancer type	MSI-H (%)	Cancer type	MSI-H (%)	Cancer type	MSI-H (%)
UCEC	17.00–31.37	BRCA	0.00–1.53	PRAD	0.60–3.00	KICH	0.00
COAD	6.00–19.72	KIRC	1.47	LUAD	0.53–1.00	KIRP	0.00
STAD	9.00–19.09	OV	1.37–2.00	BLCA	0.49	LAML	0.00
READ	5.73	CHOL	1.35–3.00	NBL	0.45	NPC	0.00
ACC	4.35	THYM	0.81	LGG	0.39	PAAD	0–2.00
UCS	3.00–3.51	LIHC	0.80–3.00	CLL	0.30	PCPG	0.00
CESC	2.62–4.00	HNSC	0.78	GBM	0.25	TGCT	0.00
WT	2.44	SARC	0.78	AML	0.00	THCA	0.00–3.00
MESO	2.41	SKCM	0.00–0.64	CTCL	0.00	UVM	0.00–2.00
ESCA	1.63	LUSC	0.60	DLBC	0.00

1. Abbreviations: UCEC uterine corpus endometrial carcinoma, COAD colon adenocarcinoma, STAD stomach adenocarcinoma, READ rectal adenocarcinoma, ACC adrenocortical carcinoma, UCS uterine carcinosarcoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, WT Wilms tumor, MESO mesothelioma, ESCA esophageal carcinoma, BRCA breast carcinoma, KIRC kidney renal clear cell carcinoma, OV ovarian serous cystadenocarcinoma, CHOL cholangiocarcinoma, THYM thymoma, LIHC liver hepatocellular carcinoma, HNSC head and neck squamous cell carcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, LUSC lung squamous cell carcinoma, PRAD prostate adenocarcinoma, LUAD lung adenocarcinoma, BLCA bladder carcinoma, NBL pediatric neuroblastoma, LGG lower-grade glioma, CLL chronic lymphocytic leukemia, GBM glioblastoma multiforme, AML pediatric acute myeloid leukemia, CTCL cutaneous T cell lymphoma, DLBC diffuse large B cell lymphoma, KICH kidney chromophobe, KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukemia, NPC nasopharyngeal carcinoma, PAAD pancreatic adenocarcinoma, PCPG pheochromocytoma and paraganglioma, TGCT testicular germ cell tumor, THCA thyroid carcinoma, UVM uveal melanoma

Journal of Hematology & Oncology